MENU
IMMP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immutep (IMMP) Ownership - Who owns Immutep?
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
264 George Street
Phone
+61 283157003
Employees
24
Web
https://www.immutep.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
243.98M
P/E Ratio
N/A
Total Cash
159.26M
Projected Growth
N/A
Total Debt
1.68M
Revenue
N/A
Risk (Beta)
1.59
Dividend Yield
N/A
Total Cash/Share
1.08
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
IMMP
Capitalization
244M
P/E Ratio
N/A
Risk (Beta)
1.59
Dividend Yield
N/A
Total Cash
159M
Total Cash/Share
1.08
Total Debt
1.69M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
172M
P/B Ratio
2.60
Cash Flow
N/A
Earnings
-0.33
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
543M
Current Ratio
18.86
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-43.83M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-28.66
Shares Held By Institutions
6.78M
Shares Outstanding - Current
147M
Total Liabilities
9.86M
Total Volume MTD
N/A
Value
-1
Gain YTD
-22.120
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information
General Information
a developer of anti-cancer therapeutics
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
264 George Street
Phone
+61 283157003
Employees
24
Web
https://www.immutep.com